MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
MetaVia (Nasdaq: MTVA) will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Company business development and clinical team members will attend the event scheduled for January 8–10, 2026 at the Chateaux Deer Valley in Park City, Utah.
This participation highlights MetaVia's engagement with the cardiometabolic and clinical research community but does not include financial or clinical readouts in this announcement.
Details
News Market Reaction – MTVA
On Dec 29, the day this news came out, MTVA closed 2.07% below the previous close.
Data tracked by StockTitan Argus for the Dec 29 session.
Key Figures
- Conference edition
- 10th Annual
- MASH-TAG 2026 conference
- Conference dates
- January 8–10, 2026
- MASH-TAG 2026 in Park City, Utah
Historical Context
-
Regained compliance with Nasdaq minimum bid requirement and closed related matter.
-
1-for-11 reverse split to address Nasdaq listing requirements and adjust share count.
-
Positive Phase 2a results for vanoglipel in presumed MASH with metabolic benefits.
-
Q3 2025 results with going-concern language despite pipeline and cash update.
-
New Phase 1 and preclinical data on DA-1726 presented at ObesityWeek 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cardiometabolic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-participate-in-and-sponsor-the-10th-annual-mash-tag-2026-conference-302649854.html
SOURCE MetaVia Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.